NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Mental Health Weekly Digest

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Mental Health Weekly Digest

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Alcoholism



FASgen Announces New Diagnostic Research Test for Steatohepatitis



June 18th, 2007

FASgen Inc. announced it has successfully expanded the potential use for its serum FAS (fatty acid synthase) ELISA diagnostic research test, FAS-Detect(TM) ELISA for the identification of Non-Alcoholic Steatohepatitis (NASH). The current diagnostic technique for this disease is a liver needle biopsy. While only for research use presently, FASgen anticipates the opportunity for use of the non-invasive FAS-Detect(TM) ELISA NASH test in the future will be substantial. FAS-Detect(TM) ELISA is a proprietary product of FASgen Diagnostics LLC, an affiliated FASgen company.

NASH commonly occurs as the result of fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is...


Source: Mental Health Weekly Digest (2007-06-18)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login